Thermo Fisher Scientific has announced the recipients of the latest Oncomine Clinical Research Grant. This grant program supports investigator-initiated studies in oncology, with a focus on molecular profiling and the democratization of precision medicine.
The grant recipients include researchers from renowned institutions such as the Melanoma Institute Australia, the University of Turin in Italy, and Atrium Health Wake Forest Baptist Medical Center. Their research projects aim to pave the way for the future to improve melanoma diagnosis, enhance treatment response in advanced non-small cell lung cancer (NSCLC), and overcome challenges in NSCLC diagnosis and treatment.
About the Oncomine Clinical Research Grant Program
The Oncomine Clinical Research Grant program has been providing significant support to independent clinical research teams since 2020. With grants awarded across 14 countries and five continents, this program has contributed to advancements in various areas of oncology research, including molecular profiling in solid tumors, pediatric oncology, hemato-oncology, immune-oncology, and liquid biopsy. The program aims to explore new applications for accessible and rapid next-generation sequencing (NGS) technology.
Jose Luis Costa, Ph.D., Global Director of Scientific Affairs, Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific, emphasized the importance of the Oncomine Clinical Research Grant program in supporting emerging research projects. He highlighted the program's commitment to harnessing the potential of NGS technology for improved clinical outcomes.
Meet the Latest Grant Recipients
The latest round of grant recipients includes four distinguished researchers and their projects:
Richard Scolyer, Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital, Australia: Richard Scolyer's project aims leverage the Melanoma Institute Australia's genomic classifier with the Ion Torrent Genexus System for melanoma clinical research.
Silvia Novello and Marco Volante, University of Turin, Italy: Silvia Novello and Marco Volante's project focuses on integrated molecular analysis to identify signatures in advanced NSCLC. The researchers aim to identify novel predictive biomarkers to enhance precision oncology.
Wencheng Li, Atrium Health Wake Forest Baptist Medical Center, United States of America: Wencheng Li's project aims to address common challenges in NSCLC. The research focuses on utilizing next-generation sequencing to assess biomarkers using supernatants from fine needle aspiration of NSCLC.
2024 Oncomine Clinical Research Grant Applications Opening Soon
Thermo Fisher Scientific will continue to support the important work of laboratories around the world in accelerating precision oncology research with the opening of applications March 1 – April 30, 2024.
To apply for the Oncomine Clinical Research Grant Program, or to learn more about the latest awardees, please visit oncomine.com/grants, and find tips and tricks for a strong application in this recent blog post.
Recently, Thermo Fisher Scientific sat down with Carolina Felix, Senior Biomedical Scientist at the Liverpool Clinical Laboratories (LCL) Molecular Pathology Service, to learn about her lab’s experience working with Thermo Fisher’s Service and...
Some NGS runs on Dr. Gabriella Gamberi’s Ion GeneStudio S5 System had a high number of low-quality reads, and she didn't know why
The stakes were high because Dr. Gabriella Gamberi's work in the pathology department at the Istituto Ortopedico...
Thermo Fisher Scientific has announced the recipients of the latest Oncomine Clinical Research Grant. This grant program supports investigator-initiated studies in oncology, with a focus on molecular profiling and the democratization of precision...
